Calendar

Nov
30
Thu
David Webb’s specialty exam: A new notion of effective dimension @ Keller Hall 402
Nov 30 @ 2:50 pm – 3:40 pm

David Webb will present a new notion of effective dimension, inescapable dimension, which is in a sense dual to complex packing dimension.

The latter was introduced by Freer and Kjos-Hanssen in 2013 in the context of trying to show that the reals of effective Hausdorff dimension 1 are not Medvedev above the bi-immune sets.

Webb will show that the two notions are incomparable, among other results.

Dec
1
Fri
Colloquium: Pamela Harris (Williams)
Dec 1 @ 3:30 pm – 4:30 pm
Talk Story with Heiner Dovermann
Dec 1 @ 3:30 pm – 4:30 pm
Dec
7
Thu
Joint Analysis/Logic Seminar @ Keller 402
Dec 7 @ 2:55 pm – 3:45 pm

Speaker : Michael Yampolsky (University of Toronto)

Title : Computability of Julia sets.

Abstract : Informally speaking, a compact set in the plane is computable if there exists an algorithm to draw it on a computer screen with an arbitrary resolution. Julia sets are some of the best-known mathematical images, however, the questions of their computability and computational complexity are surprisingly subtle. I will survey joint results with M. Braverman and others on computability and complexity of Julia sets.

Dec
8
Fri
Lei Liu’s Master presentation @ Keller Hall 401
Dec 8 @ 1:30 pm – Dec 8 @ 2:15 pm
Jan
5
Fri
Colloquium: Pamela Harris (Williams)
Jan 5 @ 3:30 pm – 4:30 pm
Jan
12
Fri
Colloquium Paul Terwilliger (U. Wisconsin) @ Keller 401
Jan 12 @ 3:30 pm – 4:30 pm
Jan
18
Thu
Undergraduate Seminar: Gideon Zamba (U. Iowa) @ Keller 402
Jan 18 @ 3:00 pm – 4:00 pm

Speaker: Gideon Zamba (U. Iowa)

Title: Recurrence of Subsequent Malignancies following Diagnosis of and Treatment for Hodgkin Lymphoma Diagnosis

Abstract: Hodgkin’s Lymphoma (HL) is a type of cancer that affects the lymphatic system and compromises the body’s ability to fight infection. HL typically starts in white blood cells. HL occurs when a specific type of cell, the Reed-Stenberg cell, is present in the host’s system, causing the body’s infection fighting cells to develop a mutation in their DNA. Each year, there are several thousand people in the United States and worldwide who develop HL. Although there are many prognostic factors for HL and post treatment malignancies, it has also been hypothesized that initial treatment after diagnosis may be associated with subsequent new malignancies or death. We explored the association between prognostic factors and subsequent malignancies using the Oncology Registry at the University of Iowa Hospitals and Clinics. In this exploration we account for subject random effect through a gamma frailty model for recurrent events, which acts multiplicatively and jointly on both the hazard of new malignancies and the hazard of death. The parameters of the model were iteratively estimated using a penalized marginal likelihood approach. The findings suggest a significant within subject correlation, and a significant treatment effect on both the hazard of recurrence and the hazard of death.